AAAAAA
Results: 226-250/265
Authors:
WILLIAMS AR
WHELAN P
Citation: Ar. Williams et P. Whelan, USE OF INTRAVENOUS FOSFESTROL TETRASODIUM (HONVAN) INFUSION IN TREATMENT OF SYMPTOMATIC ADVANCED PROSTATE-CANCER, PROSTATE CANCER AND PROSTATIC DISEASES, 1(4), 1998, pp. 204-207
Authors:
BROWN LG
WEGNER SK
WANG H
BUHLER KR
ARFMAN EW
LANGE PH
VESSELLA RL
Citation: Lg. Brown et al., A NOVEL MONOCLONAL-ANTIBODY 107-1A4 WITH HIGH PROSTATE SPECIFICITY - GENERATION, CHARACTERIZATION OF ANTIGEN EXPRESSION, AND TARGETING OF HUMAN PROSTATE-CANCER XENOGRAFTS, PROSTATE CANCER AND PROSTATIC DISEASES, 1(4), 1998, pp. 208-215
Authors:
BEAN JM
MONTANA GS
CLOUGH RW
KING SC
BENTEL GC
MARKS LB
ANSCHER MS
Citation: Jm. Bean et al., STANDARD VS CONFORMAL RADIATION-THERAPY FOR ADENOCARCINOMA OF THE PROSTATE - NO DIFFERENCE, PROSTATE CANCER AND PROSTATIC DISEASES, 1(4), 1998, pp. 216-222
Authors:
KIRBY R
JARDIN A
Citation: R. Kirby et A. Jardin, DOXAZOSIN IN THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA - A REVIEWOF THE SAFETY PROFILE IN OLDER PATIENTS (VOL 1, PG 84, 1997), PROSTATE CANCER AND PROSTATIC DISEASES, 1(4), 1998, pp. 223-223
Authors:
BELLDEGRUN A
Citation: A. Belldegrun, WHATS HOT IN THE PROSTATE, PROSTATE CANCER AND PROSTATIC DISEASES, 1(3), 1998, pp. 105-106
Citation: RECENT TRENDS IN PROSTATE-CANCER INCIDENCE AND MORTALITY, PROSTATE CANCER AND PROSTATIC DISEASES, 1(3), 1998, pp. 106-107
Authors:
KIRBY R
SCHER H
BRAWER M
Citation: R. Kirby et al., UNRAVELING THE CONFUSIONS IN PROSTATIC DISEASE, PROSTATE CANCER AND PROSTATIC DISEASES, 1(3), 1998, pp. 108-108
Authors:
MOUL JW
Citation: Jw. Moul, PROSTATE-CANCER IN AFRICAN-AMERICAN MEN, PROSTATE CANCER AND PROSTATIC DISEASES, 1(3), 1998, pp. 109-118
Authors:
LETRAN JL
BRAWER MK
Citation: Jl. Letran et Mk. Brawer, MANAGEMENT OF RADIATION FAILURE FOR LOCALIZED PROSTATE-CANCER, PROSTATE CANCER AND PROSTATIC DISEASES, 1(3), 1998, pp. 119-127
Authors:
HELGASON AR
ADOLFSSON J
DICKMAN P
FREDRIKSON M
STEINECK G
Citation: Ar. Helgason et al., DISTRESS DUE TO UNWANTED SIDE-EFFECTS OF PROSTATE-CANCER TREATMENT ISRELATED TO IMPAIRED WELL-BEING (QUALITY-OF-LIFE), PROSTATE CANCER AND PROSTATIC DISEASES, 1(3), 1998, pp. 128-133
Authors:
PENSON DF
LITWIN MS
LUBECK DP
FLANDERS S
PASTA DJ
CARROLL PR
Citation: Df. Penson et al., TRANSITIONS IN HEALTH-RELATED QUALITY-OF-LIFE DURING THE FIRST 9 MONTHS AFTER DIAGNOSIS WITH PROSTATE-CANCER, PROSTATE CANCER AND PROSTATIC DISEASES, 1(3), 1998, pp. 134-143
Authors:
KRONGRAD A
LAI H
LAI S
Citation: A. Krongrad et al., DISEASE-SPECIFIC DEATH AFTER EXTERNAL-BEAM RADIATION OF PROSTATE-CANCER, PROSTATE CANCER AND PROSTATIC DISEASES, 1(3), 1998, pp. 144-147
Authors:
GIOVANNUCCI E
KANTOFF P
SPIEGELMAN D
LOUGHLIN KR
WISHNOW KI
CORLESS C
MCDERMOTT A
WILLET WC
TALCOTT JA
Citation: E. Giovannucci et al., THE EPIDEMIC OF PROSTATE-CANCER AND THE MEDICAL LITERATURE - A CAUSALASSOCIATION, PROSTATE CANCER AND PROSTATIC DISEASES, 1(3), 1998, pp. 148-153
Authors:
KASHIF KM
FOLEY SJ
BASKETTER V
HOLMES SAV
Citation: Km. Kashif et al., HEMATURIA ASSOCIATED WITH BPH - NATURAL-HISTORY AND A NEW TREATMENT OPTION, PROSTATE CANCER AND PROSTATIC DISEASES, 1(3), 1998, pp. 154-156
Authors:
HAMMARSTEN J
HOGSTEDT B
HOLTHUIS N
MELLSTROM D
Citation: J. Hammarsten et al., COMPONENTS OF THE METABOLIC SYNDROME - RISK-FACTORS FOR THE DEVELOPMENT OF BENIGN PROSTATIC HYPERPLASIA, PROSTATE CANCER AND PROSTATIC DISEASES, 1(3), 1998, pp. 157-162
Authors:
KIRBY RS
CHAPPLE CR
SETHIA K
FLANNIGAN M
MILROY EJG
ABRAMS P
Citation: Rs. Kirby et al., MORNING VS EVENING DOSING WITH DOXAZOSIN IN BENIGN PROSTATIC HYPERPLASIA - EFFICACY AND SAFETY, PROSTATE CANCER AND PROSTATIC DISEASES, 1(3), 1998, pp. 163-171
Authors:
BELLDEGRUN A
Citation: A. Belldegrun, 5 ALPHA-REDUCTASE INHIBITOR THERAPY REDUCES THE COMPLICATIONS OF BPH, PROSTATE CANCER AND PROSTATIC DISEASES, 1(2), 1997, pp. 45-45
Authors:
BELLDEGRUN A
Citation: A. Belldegrun, NEOADJUVANT HORMONAL ABLATION ENHANCES THE RESULTS OF RADIOTHERAPY, PROSTATE CANCER AND PROSTATIC DISEASES, 1(2), 1997, pp. 45-45
Authors:
BELLDEGRUN A
Citation: A. Belldegrun, HOPE OF A NEW PROSTATE-CANCER VACCINE, PROSTATE CANCER AND PROSTATIC DISEASES, 1(2), 1997, pp. 45-46
Authors:
BELLDEGRUN A
Citation: A. Belldegrun, DR WALSH,PATRICK VISITS IRELAND, PROSTATE CANCER AND PROSTATIC DISEASES, 1(2), 1997, pp. 45-45
Authors:
BELLDEGRUN A
Citation: A. Belldegrun, PROSTATE-CANCER CHARITABLE TRUST AWARD, PROSTATE CANCER AND PROSTATIC DISEASES, 1(2), 1997, pp. 45-45
Authors:
BELLDEGRUN A
Citation: A. Belldegrun, WHATS IN THE PIPELINE, PROSTATE CANCER AND PROSTATIC DISEASES, 1(2), 1997, pp. 46-46
Authors:
KIRBY R
SCHER H
BRAWER M
Citation: R. Kirby et al., UNTITLED, PROSTATE CANCER AND PROSTATIC DISEASES, 1(2), 1997, pp. 47-47
Authors:
SALOMON L
COLOMBEL M
PATARD JJ
GASMAN D
CHOPIN D
ABBOU CC
Citation: L. Salomon et al., PROSTATE BIOPSY IN THE STAGING OF PROSTATE-CANCER, PROSTATE CANCER AND PROSTATIC DISEASES, 1(2), 1997, pp. 54-58
Authors:
ADOLFSSON J
Citation: J. Adolfsson, CONSERVATIVE MANAGEMENT OF CLINICALLY LOCALIZED PROSTATE-CANCER, PROSTATE CANCER AND PROSTATIC DISEASES, 1(2), 1997, pp. 59-65